BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Panda A, Rosenfeld JA, Singer EA, Bhanot G, Ganesan S. Genomic and immunologic correlates of LAG-3 expression in cancer. Oncoimmunology 2020;9:1756116. [PMID: 32923111 DOI: 10.1080/2162402X.2020.1756116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Gutiérrez-hoya A, Valle-mendiola A, Soto-cruz I. Immunotherapy for Cervical Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_234-1] [Reference Citation Analysis]
2 Sauer N, Szlasa W, Jonderko L, Oślizło M, Kunachowicz D, Kulbacka J, Karłowicz-bodalska K. LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors. IJMS 2022;23:9958. [DOI: 10.3390/ijms23179958] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Yu C, Li Q, Zhang Y, Wen Z, Dong H, Mou Y. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front Cell Dev Biol 2022;10:941750. [DOI: 10.3389/fcell.2022.941750] [Reference Citation Analysis]
4 Ke J, Chen J, Liu X. Analyzing and validating the prognostic value and immune microenvironment of clear cell renal cell carcinoma. Animal Cells and Systems. [DOI: 10.1080/19768354.2022.2056635] [Reference Citation Analysis]
5 Panda A, Betigeri A, Ganesan S. A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade. Front Genet 2022;13:706468. [DOI: 10.3389/fgene.2022.706468] [Reference Citation Analysis]
6 Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 2022;21:39. [PMID: 35135556 DOI: 10.1186/s12943-022-01513-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 50.0] [Reference Citation Analysis]
7 Lee CH, Jung SJ, Seo WI, Chung JI, Lee DS, Jeong DH, Jeon Y, Choi I. Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma. Int J Immunopathol Pharmacol 2022;36:3946320221125588. [PMID: 36083857 DOI: 10.1177/03946320221125588] [Reference Citation Analysis]
8 Panda A, Ganesan S. Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer. Front Genet 2021;12:706435. [PMID: 34367262 DOI: 10.3389/fgene.2021.706435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Tobin JWD, Bednarska K, Campbell A, Keane C. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells 2021;10:1152. [PMID: 34068762 DOI: 10.3390/cells10051152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Mair MJ, Kiesel B, Feldmann K, Widhalm G, Dieckmann K, Wöhrer A, Müllauer L, Preusser M, Berghoff AS. LAG-3 expression in the inflammatory microenvironment of glioma. J Neurooncol 2021;152:533-9. [PMID: 33651248 DOI: 10.1007/s11060-021-03721-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Kayukova E, Sholokhov L, Belokrinitskaya T, Tereshkov P. Checkpoint proteins in patients with precancer and cervical cancer.. [DOI: 10.1101/2021.02.09.430409] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Wuerdemann N, Pütz K, Eckel H, Jain R, Wittekindt C, Huebbers CU, Sharma SJ, Langer C, Gattenlöhner S, Büttner R, Speel EJ, Suchan M, Wagner S, Quaas A, Klussmann JP. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts. Int J Mol Sci 2020;22:E379. [PMID: 33396515 DOI: 10.3390/ijms22010379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]